Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313453973> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4313453973 endingPage "274" @default.
- W4313453973 startingPage "269" @default.
- W4313453973 abstract "<h3>Abstract</h3> Background/Aim: We aimed to clarify the association between body mass index (BMI) and clinical outcomes of pembrolizumab treatment for advanced urothelial cancer (UC). Patients and Methods: We retrospectively reviewed the records of patients with advanced UC who received pembrolizumab after chemotherapy between March 2018 and December 2021. Patients were divided according to BMI into the non-overweight group (BMI <25 kg/m<sup>2</sup>) and the overweight group (BMI ≥25 kg/m<sup>2</sup>). We compared the two groups’ tumour response, survival rates, and incidence of immune-related adverse events (irAEs) and investigated the factors predicting survival. Results: Of 84 eligible patients, 63 (75%) and 21 (25%) were in the non-overweight and overweight groups, respectively. Although the objective response rate was higher in the overweight group (55%) than that in the non-overweight group (29%), the difference was not significant. Progression-free survival (PFS) was significantly longer in the overweight group (median 15.2 months) than that in the non-overweight group (median 4.8 months; p=0.01). Overall survival was also longer in the overweight group (median 36.1 months) compared to that in the non-overweight group (13.4 months), but the difference was not significant (p=0.11). Multivariable analysis showed that overweight was significantly associated with favourable PFS. Any and severe (grade 3) irAEs were observed in 15 (24%) and 5 (7.9%) patients in the non-overweight group, respectively, and in 8 (38%) and 2 (9.5%) patients in the overweight group, respectively, but the differences were not significant. Conclusion: BMI was associated with oncological outcomes in patients with advanced UC who received pembrolizumab but not with the development of irAEs." @default.
- W4313453973 created "2023-01-06" @default.
- W4313453973 creator A5014153260 @default.
- W4313453973 creator A5020076297 @default.
- W4313453973 creator A5021124136 @default.
- W4313453973 creator A5028028767 @default.
- W4313453973 creator A5047054113 @default.
- W4313453973 creator A5048055524 @default.
- W4313453973 creator A5048188862 @default.
- W4313453973 creator A5080232364 @default.
- W4313453973 creator A5081326354 @default.
- W4313453973 creator A5082566636 @default.
- W4313453973 creator A5083263942 @default.
- W4313453973 creator A5091118998 @default.
- W4313453973 date "2022-12-30" @default.
- W4313453973 modified "2023-10-16" @default.
- W4313453973 title "Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab" @default.
- W4313453973 doi "https://doi.org/10.21873/anticanres.16159" @default.
- W4313453973 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36585166" @default.
- W4313453973 hasPublicationYear "2022" @default.
- W4313453973 type Work @default.
- W4313453973 citedByCount "0" @default.
- W4313453973 crossrefType "journal-article" @default.
- W4313453973 hasAuthorship W4313453973A5014153260 @default.
- W4313453973 hasAuthorship W4313453973A5020076297 @default.
- W4313453973 hasAuthorship W4313453973A5021124136 @default.
- W4313453973 hasAuthorship W4313453973A5028028767 @default.
- W4313453973 hasAuthorship W4313453973A5047054113 @default.
- W4313453973 hasAuthorship W4313453973A5048055524 @default.
- W4313453973 hasAuthorship W4313453973A5048188862 @default.
- W4313453973 hasAuthorship W4313453973A5080232364 @default.
- W4313453973 hasAuthorship W4313453973A5081326354 @default.
- W4313453973 hasAuthorship W4313453973A5082566636 @default.
- W4313453973 hasAuthorship W4313453973A5083263942 @default.
- W4313453973 hasAuthorship W4313453973A5091118998 @default.
- W4313453973 hasConcept C120665830 @default.
- W4313453973 hasConcept C121332964 @default.
- W4313453973 hasConcept C121608353 @default.
- W4313453973 hasConcept C126322002 @default.
- W4313453973 hasConcept C197934379 @default.
- W4313453973 hasConcept C2777701055 @default.
- W4313453973 hasConcept C2780057760 @default.
- W4313453973 hasConcept C2780221984 @default.
- W4313453973 hasConcept C2780586474 @default.
- W4313453973 hasConcept C61511704 @default.
- W4313453973 hasConcept C71924100 @default.
- W4313453973 hasConcept C90924648 @default.
- W4313453973 hasConceptScore W4313453973C120665830 @default.
- W4313453973 hasConceptScore W4313453973C121332964 @default.
- W4313453973 hasConceptScore W4313453973C121608353 @default.
- W4313453973 hasConceptScore W4313453973C126322002 @default.
- W4313453973 hasConceptScore W4313453973C197934379 @default.
- W4313453973 hasConceptScore W4313453973C2777701055 @default.
- W4313453973 hasConceptScore W4313453973C2780057760 @default.
- W4313453973 hasConceptScore W4313453973C2780221984 @default.
- W4313453973 hasConceptScore W4313453973C2780586474 @default.
- W4313453973 hasConceptScore W4313453973C61511704 @default.
- W4313453973 hasConceptScore W4313453973C71924100 @default.
- W4313453973 hasConceptScore W4313453973C90924648 @default.
- W4313453973 hasIssue "1" @default.
- W4313453973 hasLocation W43134539731 @default.
- W4313453973 hasLocation W43134539732 @default.
- W4313453973 hasOpenAccess W4313453973 @default.
- W4313453973 hasPrimaryLocation W43134539731 @default.
- W4313453973 hasRelatedWork W1866091461 @default.
- W4313453973 hasRelatedWork W2009384425 @default.
- W4313453973 hasRelatedWork W2168475707 @default.
- W4313453973 hasRelatedWork W2275480158 @default.
- W4313453973 hasRelatedWork W2374149423 @default.
- W4313453973 hasRelatedWork W2407674359 @default.
- W4313453973 hasRelatedWork W2411683087 @default.
- W4313453973 hasRelatedWork W2560382653 @default.
- W4313453973 hasRelatedWork W3114787526 @default.
- W4313453973 hasRelatedWork W3124108535 @default.
- W4313453973 hasVolume "43" @default.
- W4313453973 isParatext "false" @default.
- W4313453973 isRetracted "false" @default.
- W4313453973 workType "article" @default.